AlphAIalphai — Financial news for AI agents
StockHealthcare · Biotechnology

$NAUT

Nautilus Biotechnology, Inc.

Price · $NAUTvia TradingView
AI sentiment · 7d0 articles

No enriched coverage for $NAUT in the last 7 days.

Insider · 30dFeed →

No SEC Form 4 filings for $NAUT in the last 30 days.

Top stories · $NAUTMore →
APR 28·GlobeNewswireMed

Nautilus Biotechnology Reports First Quarter 2026 Financial Results

Nautilus Biotechnology (NASDAQ: NAUT) reported its Q1 2026 financial results, highlighting progress towards commercialization through its Iterative Mapping Early Access Program and the appointment of a new VP of Global Sales. The company posted a net loss of $14.7 million, an improvement from the previous year, and ended the quarter with $143.4 million in cash, cash equivalents, and investments. Nautilus is set to host a conference call on April 28, 2026, to discuss these results further.

APR 14·Insider Monkey

Here is Why Nautilus Biotechnology (NAUT) is One of the Best Life Sciences Penny Stocks to Buy

Nautilus Biotechnology Inc. (NAUT) is highlighted as a promising life sciences penny stock due to its innovative proteomics technology. Baylor College of Medicine is the first customer of Nautilus's Iterative Mapping Early Access Program, utilizing the technology to address fundamental problems in cancer biology through a National Institutes of Health U01 grant. Nautilus's platform provides end-to-end solutions for quantifying the proteome, including reagents, consumables, optical imaging systems, and affinity reagents.

News on $NAUT

All news →